Abstract
BackgroundThe knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required.MethodsA modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group.ResultsA strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring.ConclusionsThe recommendations based on the radiation oncology experts’ opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients.
Highlights
Prostate cancer is the second most common cancer in men worldwide
In Europe as in Spain, it has been the most frequent (360,000 cases diagnosed in the EU-27 in 2012 and 33,370 new cases in Spain in 2015) [1], with the incidence presenting a significant increase after the fifth decade
The questionnaire covered a total of 116 clinically relevant issues categorised under 7 controversial areas relating to castration-resistant prostate cancer (CRPC) and its treatment: CRPC definition, (Topic 1), Symptomatic patients (Topic 2), Diagnosis of metastasis (Topic 3), CRPC progression (Topic 4), M0 management (Topic 5), M1 management and sequencing therapy and Monitoring of response (Topic 7)
Summary
Prostate cancer is the second most common cancer in men worldwide. In recent years, in Europe as in Spain, it has been the most frequent (360,000 cases diagnosed in the EU-27 in 2012 and 33,370 new cases in Spain in 2015) [1], with the incidence presenting a significant increase after the fifth decade. Most patients initially respond to medical radiation or surgical therapy, around 10–20% of prostate cancer patients develop a castration-resistant prostate cancer (CRPC), within 5 years of follow-up [6]. The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Methods A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group. Conclusions The recommendations based on the radiation oncology experts’ opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
